ABL1 Kinase Domain Mutation Analysis

• To evaluate the basis for resistance (primary or acquired) to tyrosine kinase inhibitors (TKIs) in patients with Philadelphia-chromosome positive leukemias such as chronic myelogenous leukemia (CML) and B-acute lymphoblastic leukemia/lymphoma (B-ALL)
• Progression to accelerated phase or blast phase in CML patients

RNA is extracted from white blood cells in bone marrow, and/or peripheral blood and reverse transcribed to cDNA. Multiplex long-range PCR was performed to amplify BCR::ABL1 fusion transcripts. Libraries were prepared using the Illumina DNA preparation kit for multiplex sequencing on the MiSeq. NGS data was compared to previously derived clinical pyrosequencing and Sanger sequencing results for assay validation.

The result will include the codon number, amino acid changes and relative abundance of the mutation(s) found. A minimum of 100 BCR::ABL1 fusion copies are required to detect mutated transcript that comprise at least 5% of total BCR::ABL1 fusion transcripts in sample.

10 days

10 mls peripheral blood (PB) in purple-top (lavender top) (EDTA Vacutainer), sent on wet ice

or

2–5 ml of bone marrow aspirate (BM), sent on wet ice

81170

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.